Clinical-stage Oncology Company Beats Q4 Earnings & Revenue Estimates

Cardiff Oncology Beats Q4 Earnings and Revenue Estimates: What it Means for Investors.

Disclaimer: The author of this article has no direct investment in Cardiff Oncology. This article should not be taken as financial advice.

Cardiff Oncology (NASDAQ: $CRDF), a clinical-stage biotechnology company, has just reported its fourth quarter results. The company beat analyst consensus estimates on both earnings and revenue, marking a significant …